https://www.youtube.com/watch?v=WQnQxSoPkC8 In this video from Experts On CTEPH, Dr. Raymond L. Benza, MD, of Allegheny General Hospital, Pittsburgh, talks about the differential diagnosis of CTEPH. He defines the diseases, explains the symptoms and details how the diagnosis should be made. Learn more about…

Researchers have identified a significant risk factor that affects the prognosis of people with chronic thromboembolic pulmonary hypertension (CTEPH) in a large 26-year study. They found that elevated left ventricular filling pressure (LVFP), a measure of left heart function, was common in patients and predicted worse outcomes. Pulmonary hypertension…

Developing chronic thromboembolic pulmonary hypertension (CTEPH) within two years after a venous thromboembolism (VTE), which occurs when a blood clot forms in a vein, nearly doubles the risk of long-term death, according to a large study from Denmark. Researchers also observed that all types of pulmonary hypertension (PH)…

Actelion’s Opsumit (macitentan) made it easier for blood to pass through the lung blood vessels of chronic thromboembolic pulmonary hypertension (CTEPH) patients, a Phase 2 clinical trial suggests. In addition to lowering patients’ lung blood pressure, Opsumit also improved their ability to exercise, and was safe, researchers said. The trail…

A lot can change in five years, especially when someone has chronic thromboembolic pulmonary hypertension (CTEPH). A group of doctors at the University of Würzburg and Katharinen-Hospital Unna in Germany followed a 68-year-old woman for five years, from the time of her visiting the clinic with shortness of…

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis…

Understanding the science behind chronic thromboembolic pulmonary hypertension (CTEPH) has come a long way since, originally, a diagnosis was made postmortem. Although it is commonly underdiagnosed and undertreated, CTEPH can be cured via pulmonary endarterectomy (PEA), a technique that dates back almost to the first diagnosis of CTEPH. “At the…

Early detection of chronic thromboembolic pulmonary hypertension (CTEPH) is vital to addressing and potentially preventing the most common cause of severe pulmonary hypertension. A number of clinical diagnostic parameters have been studied and effectively practiced, but detection can extend beyond the doctor’s office. A study…

Direct oral anticoagulants — a type of blood thinner medication — are a safe and effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), according to a small study. The study, “Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension,” was published in the journal Clinics.

Researchers at the Nagoya University Graduate School of Medicine in Japan demonstrated that the endothelin receptor antagonist bosentan can improve endothelial dysfunction parameters in patients with pulmonary arterial hypertension (PAH), but not in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The findings were published in the Pulmonary…

A new sequential strategy successfully treats people with severe chronic thromboembolic pulmonary hypertension (CTEPH), significantly reducing high blood pressure and improving heart function, a study finds. The three-step regimen — medication, balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy (PEA) surgery — is designed for people facing unacceptably high surgical…

Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…